Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Zacks
BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised
BHC beats Q2 estimates as Salix, Solta Medical and Bausch + Lomb fuel growth, lifting 2026 revenue and EBITDA guidance after strong earnings.
Zacks
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
AMRN surpasses Q2 earnings estimates despite lower revenues, as cost cuts, rising demand and global partner-driven growth shape its ongoing transformation.
Zacks
Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down
RDY's fiscal Q1 earnings and revenues miss estimates as weaker North America generics sales hurt results, sending shares down 9%.
Zacks
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC
GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1 data, and strengthens its precision oncology portfolio.
Zacks
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.
Zacks
Here's Why You Should Add Savara Stock to Your Portfolio Now
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.
Zacks
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate
ACAD wins FDA's Fast Track status for remlifanserin in Alzheimer's disease psychosis as its phase II data readout approaches and phase III enrollment advances.
Zacks
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.
Zacks
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.
Zacks
<
1
2
>